The content, links, and pdfs are no longer maintained and might be outdated.
- The content on this page is being archived for historic and reference purposes only.
- For current, updated information see the MMWR website.
Erratum: Vol. 61, No. RR-3
In the MMWR Recommendations and Reports "Updated CDC Recommendations for the Management of Hepatitis B Virus–Infected Health-Care Providers and Students," an error occurred on page 4 in the second sentence of the section headed "Treatments for Chronic Hepatitis B Infection." The sentence should read, "Currently, seven therapeutic agents are approved by the Food and Drug Administration for the treatment of chronic hepatitis B, including two formulations of interferon (interferon alpha and pegylated interferon) and five nucleoside or nucleotide analogs (lamuvidine, telbivudine, adefovir, entecavir, and tenofovir)."
All MMWR HTML versions of articles are electronic conversions from typeset documents.
This conversion might result in character translation or format errors in the HTML version.
Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr)
and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S.
Government Printing Office (GPO), Washington, DC 20402-9371;
telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to firstname.lastname@example.org.